BC Extra | Mar 28, 2014
Financial News

RuiYi raises $15 million in B round

RuiYi Inc. (La Jolla, Calif.) raised $15 million in a series B round from existing investors 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; and Aravis Venture. RuiYi also hired Erik Karrer as...
BC Week In Review | May 20, 2013
Company News

Genor Biopharma, RuiYi deal

RuiYi granted Genor exclusive rights to develop and commercialize RYI-008 ( ARGX-109 ) in China. RYI-008, an anti-IL-6 mAb, is in preclinical development for cancer and autoimmune indications. RuiYi said the product will first be developed for...
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

Four years after launching a strategic venture fund, the Merck Serono S.A. unit of Merck KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million). While the fund's focus will remain...
BC Week In Review | Oct 8, 2012
Company News

Anaphore, arGEN-X B.V. deal

Anaphore changed its name to RuiYi Inc. and announced a deal for exclusive, worldwide rights to a preclinical anti-IL-6 mAb from arGEN-X. RuiYi said the moves are part of the company's shift in strategy to...
BC Extra | Oct 5, 2012
Company News

Anaphore changes name, in-licenses anti-IL6 mAb

Anaphore Inc. (La Jolla, Calif.) changed its name to RuiYi Inc. on Thursday and announced a deal for exclusive, worldwide rights to a preclinical anti-IL-6 mAb from arGEN-X B.V. (Rotterdam, the Netherlands). RuiYi said the...
BioCentury | Apr 16, 2012
Strategy

GPCR gambit

Although Anaphore Inc. has yet to enter the clinic with a program from its protein therapeutics platform, the company jumped at the opportunity to add a second biologics technology and thinks last month's stock acquisition...
BC Week In Review | Mar 26, 2012
Company News

Anaphore, RuiYi Biotechnology Inc. deal

Anaphore acquired RuiYi in a stock deal. Details were not disclosed. RuiYi discovers and develops biologics targeting GPCRs. RuiYi's co-founder Raymond Stevens joined Anaphore's board. Also joining the board is Peppi Prasit, founder and CEO...
BC Extra | Mar 23, 2012
Company News

Anaphore acquires RuiYi

Anaphore Inc. (La Jolla, Calif.) acquired RuiYi Biotechnology Inc. (Shanghai, China) in a stock deal. Details were not disclosed. RuiYi discovers and develops biologics targeting G protein-coupled receptors (GPCRs). RuiYi's co-founder Raymond Stevens joined Anaphore's...
BC Week In Review | Feb 27, 2012
Company News

Permeon management update

Permeon Biologics Inc. , Cambridge, Mass.   Business: Inflammation, Cancer, Drug delivery   Hired: Katherine Bowdish as president, CSO and a director, formerly president and CEO of Anaphore Inc.  ...
BC Week In Review | Oct 17, 2011
Company News

Anaphore board of directors update

Anaphore Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Resigned: Russell Greig as executive chairman and a director  ...
Items per page:
1 - 10 of 19
BC Extra | Mar 28, 2014
Financial News

RuiYi raises $15 million in B round

RuiYi Inc. (La Jolla, Calif.) raised $15 million in a series B round from existing investors 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; and Aravis Venture. RuiYi also hired Erik Karrer as...
BC Week In Review | May 20, 2013
Company News

Genor Biopharma, RuiYi deal

RuiYi granted Genor exclusive rights to develop and commercialize RYI-008 ( ARGX-109 ) in China. RYI-008, an anti-IL-6 mAb, is in preclinical development for cancer and autoimmune indications. RuiYi said the product will first be developed for...
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

Four years after launching a strategic venture fund, the Merck Serono S.A. unit of Merck KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million). While the fund's focus will remain...
BC Week In Review | Oct 8, 2012
Company News

Anaphore, arGEN-X B.V. deal

Anaphore changed its name to RuiYi Inc. and announced a deal for exclusive, worldwide rights to a preclinical anti-IL-6 mAb from arGEN-X. RuiYi said the moves are part of the company's shift in strategy to...
BC Extra | Oct 5, 2012
Company News

Anaphore changes name, in-licenses anti-IL6 mAb

Anaphore Inc. (La Jolla, Calif.) changed its name to RuiYi Inc. on Thursday and announced a deal for exclusive, worldwide rights to a preclinical anti-IL-6 mAb from arGEN-X B.V. (Rotterdam, the Netherlands). RuiYi said the...
BioCentury | Apr 16, 2012
Strategy

GPCR gambit

Although Anaphore Inc. has yet to enter the clinic with a program from its protein therapeutics platform, the company jumped at the opportunity to add a second biologics technology and thinks last month's stock acquisition...
BC Week In Review | Mar 26, 2012
Company News

Anaphore, RuiYi Biotechnology Inc. deal

Anaphore acquired RuiYi in a stock deal. Details were not disclosed. RuiYi discovers and develops biologics targeting GPCRs. RuiYi's co-founder Raymond Stevens joined Anaphore's board. Also joining the board is Peppi Prasit, founder and CEO...
BC Extra | Mar 23, 2012
Company News

Anaphore acquires RuiYi

Anaphore Inc. (La Jolla, Calif.) acquired RuiYi Biotechnology Inc. (Shanghai, China) in a stock deal. Details were not disclosed. RuiYi discovers and develops biologics targeting G protein-coupled receptors (GPCRs). RuiYi's co-founder Raymond Stevens joined Anaphore's...
BC Week In Review | Feb 27, 2012
Company News

Permeon management update

Permeon Biologics Inc. , Cambridge, Mass.   Business: Inflammation, Cancer, Drug delivery   Hired: Katherine Bowdish as president, CSO and a director, formerly president and CEO of Anaphore Inc.  ...
BC Week In Review | Oct 17, 2011
Company News

Anaphore board of directors update

Anaphore Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Resigned: Russell Greig as executive chairman and a director  ...
Items per page:
1 - 10 of 19